The cost of several anti-cancer medicines in India is set to come down from November 9, 2026, following a price-control intervention by the National Pharmaceutical Pricing Authority (NPPA). The measure covers 137 identified non-scheduled anti-cancer drugs and aims to make essential cancer treatment more affordable by restricting excessive trade margins across the distribution chain.
According to the Department of Pharmaceuticals, 76 pharmaceutical companies have reported revised maximum retail prices (MRPs) for 1,225 anti-cancer formulations, covering 121 drugs. Price reductions have been reported in 1,031 formulations. Among these, 600 brands have reported reductions exceeding 50%, while the highest reported reduction stands at 96.45%.
Editorial Insight
Key Highlights
Important points readers should notice.
Issue/Event: Revised prices for several anti-cancer medicine formulations following trade-margin rationalisation.
Location: India.
Authority/Organisation: National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals.
Action Taken: Trade margins capped at a maximum of 30% for 137 identified non-scheduled anti-cancer drugs; revised prices effective November 9, 2026.
Impact: Price reductions reported in 1,031 formulations, with estimated annual consumer savings of ₹3,502.31 crore.
The government estimates that the revised prices could generate annual savings of approximately ₹3,502.31 crore for consumers.
The intervention follows a recommendation by an expert committee constituted by the Directorate General of Health Services under the Ministry of Health and Family Welfare. Using its powers under Paragraph 19 of the Drugs (Prices Control) Order, 2013, the NPPA has rationalised trade margins for the identified medicines, with a maximum permissible trade margin of 30%.
The revised prices apply from November 9. Manufacturers, retailers, dealers, hospitals and medical institutions are required to ensure that patients are charged according to the applicable revised MRPs. The government has also directed that updated price lists be prominently displayed at pharmacies, hospitals and on relevant websites.
Editorial Analysis
Why This Matters
Cancer treatment can involve repeated medicine purchases over extended periods, creating a substantial financial burden for patients and their families. Reducing excessive trade margins can improve the affordability of selected medicines and help patients access prescribed treatments at lower prices. The measure also places greater responsibility on manufacturers, distributors, retailers and hospitals to follow the revised pricing requirements. For consumers, the key issue will be whether the revised MRPs are correctly implemented at pharmacies and medical institutions from the effective date.
The price changes affect medicines used in the treatment of several types of cancer. The government has highlighted drugs and formulations involving treatments for breast, prostate, lung, colon, ovarian and cervical cancers, among others.
Examples published by the government illustrate the scale of some reported reductions. The MRP of Zydus Lifesciences' Bryxta, a Bevacizumab 100 mg injection, has been revised from ₹25,995 to ₹3,318. The reported MRP of Abirone, an Abiraterone acetate 250 mg tablet brand, has changed from ₹41,250 to ₹3,218.23. These are brand-specific examples; patients should verify the exact formulation, strength, manufacturer and applicable revised price before purchasing.
The government has clarified that 10–15 of the 137 identified drugs are yet to be launched in India. The trade-margin rationalisation will also apply to those medicines when they enter the Indian market.
To help consumers verify prices, the NPPA has made revised price lists available through its official website. Patients and caregivers can also use the Pharma Sahi Daam mobile application to check medicine prices. A helpline has been provided for reporting violations.
The measure is significant for families managing long-term cancer treatment, where medicine costs can add substantially to hospital, diagnostic and other medical expenses. However, the actual savings will depend on the specific medicine, brand, formulation and treatment prescribed. Patients should consult their treating doctors and verify the updated MRP rather than changing medicines or treatment plans independently.
